William E Brady
Overview
Explore the profile of William E Brady including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brown J, Naumann R, Brady W, Coleman R, Moore K, Gershenson D
Gynecol Oncol
. 2018 Apr;
149(3):605-611.
PMID: 29699802
Background: Performing clinical trials in rare gynecologic cancers presents specific challenges. Strategies for improving accrual and modifications in clinical trial design are outlined. Methods: The literature was reviewed in order...
12.
Oliver K, Brady W, Birrer M, Gershenson D, Fleming G, Copeland L, et al.
Gynecol Oncol
. 2017 Aug;
147(2):243-249.
PMID: 28807367
Purpose: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). Methods: We reviewed data from FIGO stage I-IV epithelial ovarian...
13.
Thaker P, Brady W, Lankes H, Odunsi K, Bradley W, Moore K, et al.
Gynecol Oncol
. 2017 Aug;
147(2):283-290.
PMID: 28802766
Objective: The study's purpose was to assess safety and efficacy of escalating doses of weekly GEN-1 with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian...
14.
Jandial D, Brady W, Howell S, Lankes H, Schilder R, Beumer J, et al.
Gynecol Oncol
. 2017 Mar;
145(2):236-242.
PMID: 28341300
Purpose: Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is...
15.
Lin H, Mares J, LaMonte M, Brady W, Sahli M, Klein R, et al.
Ophthalmic Epidemiol
. 2017 Mar;
24(5):311-322.
PMID: 28332910
Purpose: To examine the association between xanthophyll intake and prevalent early age-related macular degeneration (AMD) using data from the Atherosclerosis Risk in Communities Study (n = 10,295). Potential effect modification...
16.
Monk B, Facciabene A, Brady W, Aghajanian C, Fracasso P, Walker J, et al.
Clin Cancer Res
. 2016 Oct;
23(8):1955-1966.
PMID: 27702821
Immunotherapy is an emerging paradigm for the treatment of cancer, but the potential efficacy of many drugs cannot be sufficiently tested in the mouse. We sought to develop a rational...
17.
Sahli M, Mares J, Meyers K, Klein R, Brady W, Klein B, et al.
Ophthalmic Epidemiol
. 2016 Mar;
23(2):99-108.
PMID: 26949989
Purpose: We tested the hypothesis that dietary intake of lutein is inversely associated with prevalence of diabetic retinopathy (DR) due to its antioxidant and anti-inflammatory properties and location within the...
18.
Griffiths E, Brady W, Tan W, Vigil C, Thompson J, Ford L, et al.
Leuk Res
. 2016 Mar;
43:44-8.
PMID: 26943703
Relapsed/refractory (r/r) Acute Myeloid Leukemia (AML) remains a therapeutic challenge. Cytarabine arabinoside (AraC) forms the backbone of most regimens, with complete responses (CR) ranging from 17 to 20%. Lenalidomide (Len)...
19.
Landrum L, Brady W, Armstrong D, Moore K, DiSilvestro P, OMalley D, et al.
Gynecol Oncol
. 2015 Dec;
140(2):204-9.
PMID: 26616225
Objective: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of veliparib combined with PLD and carboplatin (CD) in patients with recurrent, platinum-sensitive epithelial ovarian cancer. To determine...
20.
Rocconi R, Lankes H, Brady W, Goodfellow P, Ramirez N, Alvarez R, et al.
Gynecol Oncol
. 2015 Nov;
140(2):264-9.
PMID: 26603970
Purpose: Racial genetic admixture (RGA), a measure to account for ancestral genetic background that correlates with individual's racial classification, could provide insights on causation of racial disparity in endometrial cancer...